

09/27/2005 00:34

6102705253

GSK

PAGE 01/12

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Commissioner for Patents: Box: PCT at
(571) 273 3201 on 27 September 2005 by Arlene E Cannon

Arlene E Cannon

Total Pages 12

Attorney Docket No.: P33121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Forbes et al.
Serial No.: 10/530,538
Filed: 6 October 2003
For: SULFONAMIDES DERIVATIVES AS ANTIPYSCHOTIC AGENTS

Commissioner for Patents
Mail Stop: PCT
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Sir:

This facsimile is in response to the "Notification of Missing Requirements under 35 U.S.C. 371" mailed on 2 September 2005, which indicates that the Oath or Declaration of the inventors for the subject patent application is not part of the filewrapper. A copy of the above notice is attached.

Also enclosed, please find a Declaration for the subject patent application, which has been fully executed by the inventors of the subject patent application in compliance with 37 C.F.R. 1.497(a), and (b), and Power of Attorney and Statement under 37 C.F.R. 3.73(b).

Applicants' application does not contain a disclosure of nucleotide or amino acid sequences per se, as defined by 37 CFR §1.821(a) and (b), but merely set out literature references containing information about phosphodiesterases 3, 4, 5 and 6. Therefore there is not requirement to provide sequence data under the provisions of 37 CFR §1.821(c), 37 CFR §1.821(e), 37 CFR §1.821(f), 37 CFR §1.821(g), 37 CFR §1.821(e), or 37 CFR §1.825(b), or 37 CFR §1.825(d).

Please charge the \$130.00 surcharge for late filing of the fully executed declaration to Deposit Account No. 19-2570. Please charge any additional requisite fees for the filing of the enclosed Declaration or credit any over-payment to Deposit Account No. 19-2570.

Respectfully submitted,

James M. Kahan

James M. Kahan/9/2005 BCAMPBEL 00000009 192570 10530538
Attorney for Applicants
Registration No. 29,550 130.00 DA

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014 Fax (610) 270-5090

BEST AVAILABLE COPY

09/27/2005 00:34 6102705253

GSK

PAGE 02/12
Page 1 of 3



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/530,538	Ian Thomson Forbes	P33121

INTERNATIONAL APPLICATION NO.
PCT/EP03/11174

I.A. FILING DATE	PRIORITY DATE
10/06/2003	10/07/2002

20462
SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

CONFIRMATION NO. 4716
371 FORMALITIES LETTER



Date Mailed: 09/02/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 04/06/2005
- Copy of the International Search Report filed on 04/06/2005
- Copy of IPE Report filed on 04/06/2005
- Preliminary Amendments filed on 04/06/2005
- Information Disclosure Statements filed on 04/06/2005
- Request for Immediate Examination filed on 04/06/2005
- U.S. Basic National Fees filed on 04/06/2005
- Priority Documents filed on 04/06/2005
- Specification filed on 04/06/2005
- Claims filed on 04/06/2005
- Abstracts filed on 04/06/2005



The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

BEST AVAILABLE COPY

Total additional fees required for this application is \$130 for a Large Entity:

• \$130 Surcharge.

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/530,538	PCT/EP03/11174	P33121

BEST AVAILABLE COPY